Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
Giles, F J, Abruzzese, E, Rosti, G, Kim, D-W, Bhatia, R, Bosly, A, Goldberg, S, Kam, G L S, Jagasia, M, Mendrek, W, Fischer, T, Facon, T, Dünzinger, U, Marin, D, Mueller, M C, Shou, Y, Gallagher, N J, Larson, R A, Mahon, F-X, Baccarani, M, Cortes, J, Kantarjian, H M
Published in Leukemia (01.07.2010)
Published in Leukemia (01.07.2010)
Get full text
Journal Article